Shahrokh Shariat - Biography#

Dr. Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology at Weill Cornell Medical Center, New York, NY; adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA; adjunct professor of urology at the Faculty of Medicine, Charles University, Prague, CZ; adjunct professor of urology at I.M. Sechenov First Moscow State Medical University, Moscow, RU; honorary professor of urology, University of Jordan, Amman, JO; and doctor honoris causa, Carol Davila University of Medicine and Pharmacy, Bucharest, RO.

He has published more than 1570 peer-reviewed research papers (Scopus h-index 113, 51593 citations; Google scholar h-index 135, 72198 citations), >600 non-peer-reviewed papers, and 26 book chapters. He is the holder of four patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international awards. He has, for example, received the prestigious Matula Award from the European Urological Association and the Gold Cystoscope 2017 from the American Urological Association. He is a member of 25 academic societies and editorial board of 26 scientific journals.

He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of various journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology (editor in chief), among others. He heads a medical charity for refugees and is on the medical advisory board for two other charities.

His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. Specially, Dr. Shariat's has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.